BR0316010A - Combinação - Google Patents

Combinação

Info

Publication number
BR0316010A
BR0316010A BR0316010-6A BR0316010A BR0316010A BR 0316010 A BR0316010 A BR 0316010A BR 0316010 A BR0316010 A BR 0316010A BR 0316010 A BR0316010 A BR 0316010A
Authority
BR
Brazil
Prior art keywords
docetaxel
prodrug
derivative
relates
cdk inhibitor
Prior art date
Application number
BR0316010-6A
Other languages
English (en)
Inventor
Athos Giannella-Borradori
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0225872.1A external-priority patent/GB0225872D0/en
Priority claimed from GB0318813A external-priority patent/GB0318813D0/en
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Publication of BR0316010A publication Critical patent/BR0316010A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

Abstract

"COMBINAçãO". A presente invenção refere-se a uma combinação compreendendo docetaxel, ou um seu derivado ou pró-droga, e Inibidor de CDK. Um segundo aspecto da invenção refere-se a um produto farmacêutico compreendendo docetaxel, ou um seu derivado ou pró-droga, e um inibidor de CDK como uma preparação combinada para uso simultâneo, seq³encial ou separado em terapia. Um terceiro aspecto da invenção refere-se a um método de tratamento de um distúrbio proliferativo, o dito método compreendendo administrar simultaneamente, seq³encialmente ou separadamente docetaxel, ou um seu derivado ou pró-droga, e um inibidor de CDK a um indivíduo.
BR0316010-6A 2002-11-06 2003-11-05 Combinação BR0316010A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0225872.1A GB0225872D0 (en) 2002-11-06 2002-11-06 Combination
GB0318813A GB0318813D0 (en) 2003-08-11 2003-08-11 Combination
PCT/GB2003/004780 WO2004041268A1 (en) 2002-11-06 2003-11-05 Combination comprising docetaxel and a cdk inhibitor

Publications (1)

Publication Number Publication Date
BR0316010A true BR0316010A (pt) 2005-09-13

Family

ID=32313983

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316010-6A BR0316010A (pt) 2002-11-06 2003-11-05 Combinação

Country Status (11)

Country Link
US (1) US20050277656A1 (pt)
EP (1) EP1558242B1 (pt)
JP (1) JP4764165B2 (pt)
AT (1) ATE418333T1 (pt)
AU (1) AU2003276467A1 (pt)
BR (1) BR0316010A (pt)
CA (1) CA2502973A1 (pt)
DE (1) DE60325502D1 (pt)
ES (1) ES2318202T3 (pt)
MX (1) MXPA05004917A (pt)
WO (1) WO2004041268A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
US20070287718A1 (en) * 2003-11-06 2007-12-13 Green Simon R Methods for the Treatment of Multiple Myeloma Using Roscovitine
JP5537035B2 (ja) * 2006-02-10 2014-07-02 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Ｃｄｋ阻害剤、および成長因子抗体または抗有糸***剤を含む組合せ
EP2596801B1 (en) * 2006-10-06 2018-05-02 Bavarian Nordic A/S Recombinant modified vaccinia ankara virus encoding a her-2 antigen for use in treating cancer
EP2178531A4 (en) * 2007-07-02 2012-01-11 Yu Ming METHODS AND COMPOSITIONS, TARGETS FOR COMBINED CANCER TREATMENTS
EP2874631A1 (en) 2012-05-15 2015-05-27 Cyclacel Limited Dosage regimen for sapacitabine and seliciclib

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6235776B1 (en) * 1998-11-12 2001-05-22 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a paclitaxel derivative
GB9904932D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
JP2004538247A (ja) * 2000-12-08 2004-12-24 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー セミカルバジド及びサイクリン依存キナーゼ阻害剤
UY27220A1 (es) * 2001-03-23 2002-09-30 Aventis Pharma Sa Combinación de un taxano con una quinasa ciclina-dependiente
US6949558B2 (en) * 2001-11-07 2005-09-27 Yale University Enhancement of taxane-based chemotherapy by a CDK1 antagonist
CN1652844A (zh) * 2002-03-15 2005-08-10 西克拉塞尔有限公司 用于癌症治疗的cdk抑制剂和5－fu的联合
CA2502979A1 (en) * 2002-11-06 2004-05-21 Cyclacel Limited Pharmaceutical composition comprising a cdk inhibitor and gemcitabine
GB0225873D0 (en) * 2002-11-06 2002-12-11 Cyclacel Ltd Combination
BR0316021A (pt) * 2002-11-06 2005-09-27 Cyclacel Ltd Comibinação compreendendo um inibidor de cdk e cisplatina

Also Published As

Publication number Publication date
JP4764165B2 (ja) 2011-08-31
ES2318202T3 (es) 2009-05-01
MXPA05004917A (es) 2005-08-18
ATE418333T1 (de) 2009-01-15
EP1558242A1 (en) 2005-08-03
US20050277656A1 (en) 2005-12-15
WO2004041268A1 (en) 2004-05-21
AU2003276467A1 (en) 2004-06-07
EP1558242B1 (en) 2008-12-24
CA2502973A1 (en) 2004-05-21
JP2006508186A (ja) 2006-03-09
DE60325502D1 (de) 2009-02-05

Similar Documents

Publication Publication Date Title
MXPA05004919A (es) Composicion farmaceutica que comprende un inhibidor cdk y gemcitabina.
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
BRPI0507482A (pt) combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap
TW200612922A (en) Inhibitors of hsp90
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
TW200633700A (en) Methods of using temozolomide formulation intrathecally in the treatment of cancers
ATE396986T1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
GB0328180D0 (en) Combination
BR0307629A (pt) Métodos e composições para tratar condições hiperproliferativas
ATE523200T1 (de) Kombination mit sapacitibin (2'-cyano-2'-desoxy- n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosin) und einem zytotoxischen mittel
ATE353650T1 (de) Kombinationstherapie zur behandlung von krebs
BR0316010A (pt) Combinação
MXPA04009012A (es) Combinacion de inhibidor ofa cdk y 5 fu para el tratamiento de cancer.
MXPA05004920A (es) Combinacion que comprende un inhibidor cdk y cisplatin.
BR0316029A (pt) Combinação
MXPA04009396A (es) Combinacion que comprende un inhibidor cdk y doxorubicina.
WO2007054725A3 (en) Combination of a cdk-inhibitor and a hdac-inhibitor
WO2007146375A3 (en) Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer
ECSP055700A (es) Uso de derivados de 4-piridil-metil-ftalazina para la fabricación de un medicamento para el tratamiento de síndromes mielodisplásticos
TW200500073A (en) Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof
DE60318041D1 (de) Synergistische kombination eines opiatanalgetikums und eines nsaid
MX2007002532A (es) Metodos para el tratamiento de enfermedades proliferativas de la piel utilizando derivados de carbazol.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]